Zealand's ZP9830 SAD data clear safety bar; MAD readout due H2 2026
Single doses of the Kv1.3 blocker showed no dose-limiting toxicity and dose-dependent target engagement, setting up multiple-dose safety data as the next test for Zealand Pharma's chronic-inflammation entry.
Executive Summary
- Zealand Pharma has already cleared the single-dose safety bar for its Kv1.3 ion channel blocker, with no serious adverse events or dose-limiting findings and evidence the drug engages its target in a dose-dependent way.
- The open question shifts to repeat dosing: multiple-dose data due later this year will determine whether that clean safety profile holds when participants receive the drug more than once.
- A tolerable multiple-dose profile would clear the path to testing ZP9830 in patients with the inflammatory condition it targets, the next step the sponsor has already outlined.
- No other industry-sponsored trial anywhere in development currently targets the Kv1.3 ion channel in this way, leaving ZP9830 without a direct comparator to benchmark against.
The result so far
Zealand Pharma reported topline results from the single ascending dose (SAD) portion of its combined Phase 1a SAD/MAD trial of ZP9830, a Kv1.3 ion channel blocker, in its first-quarter 2026 update. Single doses were well tolerated, with no serious or severe adverse events and no dose-limiting safety findings at any dose level tested. Pharmacokinetics tracked predictions, and exploratory pharmacodynamic biomarkers showed dose-dependent engagement of the Kv1.3 target, the mechanistic signal the sponsor needs before advancing the drug. ZealandZealand Pharma Announces Financial Results for the First Three Months of 2026May 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What comes next
The trial, registered as NCT06682975 and running in the Netherlands, is designed to test single and multiple ascending doses of ZP9830 in 124 healthy adult male participants. The primary endpoint is the incidence of treatment-emergent adverse events, a safety measure rather than an efficacy one. Zealand Pharma has said it expects topline data from the multiple ascending dose (MAD) part in the second half of 2026, with a stated window running from July 1 through December 31, 2026. NCT06682975+1A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy ParticipantsNCT06682975Zealand Pharma Announces Financial Results for the First Three Months of 2026May 7, 2026
Trial mechanics
The registry lists a primary completion date of August 1, 2026, moved out from an earlier December 1, 2025 date, and an anticipated enrollment of 124 participants, up from 92. Both changes were logged in the same February 17, 2026 registry update and sit within the routine band for a Phase 1 design; an enrollment increase at this stage is a normal operational adjustment, not a sign of trouble. The trial remains in Recruiting status as of this writing. NCT06682975A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy ParticipantsNCT06682975
The competitive frame
No industry-sponsored trial in the current landscape shares ZP9830's Kv1.3 ion channel blocker target, leaving the asset without a direct comparator on mechanism. The nearest peers in the same indication category work through unrelated targets, from CETP and PKD1 inhibitors to an HIV capsid inhibitor, none of which speak to how a Kv1.3 blocker will perform on repeat dosing. Zealand Pharma's own portfolio has completed 27 of 29 trials with two terminated, a track record that provides operational context but says nothing about this specific mechanism's tolerability.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.